Table 1

Characteristics, comorbidities, and medication use in subjects treated and not treated with acarbose

VariableSubjects with diabetes (n = 398,592)Subjects treated with acarbose (>0 cDDD) (n = 199,296)Subjects not treated with acarbose (0 cDDD) (n = 199,296)
Age (years)
 18–297,283 (1.83)3,657 (1.83)3,626 (1.82)
 30–397,283 (1.83)3,657 (1.83)3,626 (1.82)
 40–4935,764 (8.97)17,872 (8.97)17,892 (8.98)
 50–59101,628 (25.5)50,831 (25.51)50,797 (25.49)
 ≥60119,449 (29.97)59,705 (29.96)59,744 (29.98)
 Median (IQR)54.1 (46.3–63.7)54.1 (46.3–63.7)54.1 (46.3–63.7)
Sex
 Male209,306 (52.51)104,653 (52.51)104,653 (52.51)
Follow-up period (years)
 Median (IQR)3.4 (1.7–5.5)3.5 (1.7–5.6)3.4 (1.7–5.5)
Income (NTD)
 061,083 (15.32)30,202 (15.15)30,881 (15.50)
 1–15,84060,717 (15.23)30,389 (15.25)30,328 (15.22)
 15,840–25,000191,524 (48.05)97,342 (48.84)94,182 (47.26)
 >25,00085,268 (21.39)41,363 (20.75)43,905 (22.03)
Urbanization
 Low116,217 (29.16)57,510 (28.86)58,707 (29.46)
 Moderate182,909 (45.89)90,764 (45.54)92,145 (46.24)
 High65,006 (16.31)32,425 (16.27)32,581 (16.35)
 Very high34,460 (8.65)18,597 (9.33)15,863 (7.96)
Acarbose (cDDD)
 0199,296 (50.00)0 (0)199,296 (100)
 >0 to <90104,281 (26.16)104,281 (52.32)0 (0)
 90 to 36462,714 (15.73)62,714 (31.47)0 (0)
 ≥36532,301 (8.10)32,301 (16.21)0 (0)
 Median (IQR)83.0 (21.0–242.7)
Diabetes duration (years)
 <9202,239 (50.74)101,159 (50.76)101,080 (50.72)
 ≥9196,353 (49.26)98,137 (49.24)98,216 (49.28)
Metformin283,905 (71.23)161,431 (81.00)122,474 (61.45)
Sulfonylurea287,101 (72.03)167,120 (83.86)119,981 (60.20)
TZD108,512 (27.22)75,636 (37.95)32,876 (16.50)
Insulin120,477 (30.23)77,389 (38.83)43,088 (21.62)
Aspirin168,836 (42.36)91,862 (46.09)76,974 (38.62)
Statin192,313 (48.25)107,700 (54.04)84,613 (42.46)
NSAID337,243 (84.61)170,502 (85.55)166,741 (83.67)
Medical diseases
 Inflammatory bowel disease5,970 (1.50)2,985 (1.50)2,985 (1.50)
 Colon polyp6,808 (1.71)3,404 (1.71)3,404 (1.71)
 Hypertension293,500 (73.63)146,750 (73.63)146,750 (73.63)
 Hyperlipidemia297,546 (74.65)148,773 (74.65)148,773 (74.65)
 Surveillance colonoscopy22,728 (5.70)11,241 (5.64)11,487 (5.76)
 FOBT44,733 (11.22)24,661 (12.37)20,072 (10.07)
 aDCSI score0.39 (1.26)0.48 (1.37)0.31 (1.13)
  • Data are n (%) or mean (SD) unless otherwise indicated. IQR, interquartile range; NTD, New Taiwan Dollar.

  • †The median prescribed number of study drug doses used (>0 cDDD) in the cohort.